Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

• Main Authors: Ibrahim Tekedereli (Author), S Neslihan Alpay (Author), Ugur Akar (Author), Erkan Yuca (Author), Cristian Ayugo-Rodriguez (Author), He-Dong Han (Author), Anil K Sood (Author), Gabriel Lopez-Berestein (Author), Bulent Ozpolat (Author)
• Format: Book
• Published: Elsevier, 2013-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bcl-2 is overexpressed in about a half of human cancers and 50-70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...